

Registered number: 09707843

**STRIDES PHARMA GLOBAL (UK) LTD**  
**DIRECTORS' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**COMPANY INFORMATION**

---

<b>Directors</b>	Mr M K Pillai (resigned 10 June 2020) Mr V Kumar Mr K T Parthasarathy
<b>Registered number</b>	09707843
<b>Registered office</b>	Unit 4 Metro Centre Tolpits Lane Watford Hertfordshire WD18 9SS
<b>Independent auditor</b>	MHA MacIntyre Hudson Chartered Accountants & Statutory Auditors 6th Floor 2 London Wall Place London EC2Y 5AU

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**CONTENTS**

---

	Page
<b>Directors' report</b>	1 - 2
<b>Independent auditor's report</b>	3 - 6
<b>Statement of comprehensive income</b>	7
<b>Balance sheet</b>	8
<b>Notes to the financial statements</b>	9 - 15
The following pages do not form part of the statutory financial statements:	
<b>Detailed profit and loss account and summaries</b>	16 - 17

---

## **STRIDES PHARMA GLOBAL (UK) LTD**

---

### **DIRECTORS' REPORT FOR THE YEAR ENDED 31 MARCH 2021**

---

The directors present their report and the financial statements for the year ended 31 March 2021.

#### **Principal activity**

The principal activity of the company is the holding of investments.

#### **Directors**

The directors who served during the year were:

Mr M K Pillai (resigned 10 June 2020)  
Mr V Kumar  
Mr K T Parthasarathy

#### **Directors' responsibilities statement**

The directors are responsible for preparing the Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the Company's financial statements and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

#### **Disclosure of information to auditor**

Each of the persons who are directors at the time when this Directors' report is approved has confirmed that:

- so far as the director is aware, there is no relevant audit information of which the Company's auditor is unaware, and
- the director has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**DIRECTORS' REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 MARCH 2021**

---


**Auditor**

The auditor, MHA MacIntyre Hudson, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.

**Small companies note**

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.

  
.....  
**Mr K T Parthasarathy**  
Director

Date: **September 24, 2021**

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF STRIDES PHARMA GLOBAL (UK) LTD**

---

**Opinion**

We have audited the financial statements of Strides Pharma Global (UK) Ltd (the 'Company') for the year ended 31 March 2021, which comprise the Statement of comprehensive income, the Balance sheet and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Company's affairs as at 31 March 2021 and of its loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Our evaluation of the directors' assessment of the entity's ability to continue to adopt the going concern basis of accounting including :

- Reviewing post year end information including board minutes, cash position and management accounts;
- Obtaining letter of support from the parent company;
- Considering the impact of COVID on the future performance.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF STRIDES PHARMA GLOBAL (UK) LTD (CONTINUED)**

---

**Other information**

The directors are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**Opinion on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' report has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Directors' report and from the requirement to prepare a Strategic report.

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF STRIDES PHARMA GLOBAL (UK) LTD (CONTINUED)**

---

**Responsibilities of directors**

As explained more fully in the Directors' responsibilities statement set out on page 1, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- Enquiry of management and those charged with governance around actual and potential litigation and claims;
- Performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias.
- Reviewing minutes of meetings of those charged with governance;
- Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Auditor's report.

---

**STRIDES PHARMA GLOBAL (UK) LTD**


---

**INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS OF STRIDES PHARMA GLOBAL (UK) LTD (CONTINUED)**

---

**Use of our report**

This report is made solely to the Company's shareholders, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's shareholders those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's shareholders, as a body, for our audit work, for this report, or for the opinions we have formed.



Rakesh Shaunak FCA (Senior Statutory Auditor)  
for and on behalf of  
**MHA MacIntyre Hudson**  
Chartered Accountants  
Statutory Auditors  
6th Floor  
2 London Wall Place  
London  
EC2Y 5AU  
Date: 24 September 2021

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**STATEMENT OF COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 31 MARCH 2021**

---

	2021 £	2020 £
Administrative expenses	(1,980,066)	(239,021)
Fair value movements	249,947	(1,129,482)
<b>Operating loss</b>	<b>(1,730,119)</b>	<b>(1,368,503)</b>
Income from fixed assets investments	-	2,001,600
<b>(Loss)/profit before tax</b>	<b>(1,730,119)</b>	<b>633,097</b>
Tax on (loss)/profit	(47,470)	-
<b>(Loss)/profit for the financial year</b>	<b>(1,777,589)</b>	<b>633,097</b>

There was no other comprehensive income for 2021 (2020:£NIL).

The notes on pages 9 to 15 form part of these financial statements.

---

**STRIDES PHARMA GLOBAL (UK) LTD**  
**REGISTERED NUMBER:09707843**

---

**BALANCE SHEET**  
**AS AT 31 MARCH 2021**

---

	Note	2021 £	2020 £
<b>Fixed assets</b>			
Investments	5	<b>20,194,918</b>	19,918,292
		<u>20,194,918</u>	<u>19,918,292</u>
<b>Current assets</b>			
Debtors: amounts falling due within one year	6	<b>87,925</b>	496,378
Cash at bank and in hand	7	<b>170,288</b>	16,232
		<u>258,213</u>	<u>512,610</u>
Creditors: amounts falling due within one year	8	<b>(5,063,031)</b>	(3,263,213)
<b>Net current liabilities</b>		<b>(4,804,818)</b>	(2,750,603)
<b>Total assets less current liabilities</b>		<b>15,390,100</b>	17,167,689
<b>Net assets</b>		<b>15,390,100</b>	17,167,689
<b>Capital and reserves</b>			
Called up share capital	10	<b>43,357,438</b>	43,357,438
Profit and loss account		<b>(27,967,338)</b>	(26,189,749)
<b>Shareholder's funds</b>		<b>15,390,100</b>	17,167,689

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on

  
**Mr K T Parthasarathy**  
Director

The notes on pages 9 to 15 form part of these financial statements.

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021**

---

**1. General information**

Strides Pharma Global (UK) Ltd is a company limited by shares incorporated in England and Wales. The address of the registered office is Unit 4 Metro Centre, Tolpits Lane, Watford, Hertfordshire, WD18 9SS. The financial statements cover the period from 1 April 2020 to 31 March 2021.

**2. Accounting policies**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

**2.2 Going concern**

The financial statements have been prepared on a going concern basis. The Directors have considered relevant information, including the annual budget, forecast future cash flows and the impact of subsequent events in making their assessment. The Directors have also considered the availability of continued financial support from the parent company – Strides Pharma Science Limited, in evaluating their assessment. The Strides Group has continued to trade through the COVID-19 pandemic as "essential" categorised entities (being manufacturer and wholesaler of pharmaceutical goods) and the forecasts and budgets suggest the group will continue to do so. In response to the COVID-19 pandemic, the Directors have performed a robust analysis of forecast future cash flows taking into account the potential impact on the business of possible future scenarios arising from the impact of COVID-19. This analysis also considers the effectiveness of available measures to assist in mitigating the impact.

The Company made a loss of £1,777,589 (2020: profits of £633,097) and, as at the year end date its current liabilities exceeded its current assets by £4,804,818 (2020: £2,750,603). The Company has its investment in subsidiaries operating in EU and USA markets and the management believes that there is a huge potential for these subsidiaries to be able to help the Company realise its assets and discharge its liabilities.

Based on these assessments and having regard to the resources available to the entity, the Directors have concluded that there is no material uncertainty and that they can continue to adopt the going concern basis in preparing the annual report and accounts.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021

---

2. Accounting policies (continued)

2.3 Foreign currency translation

**Functional and presentation currency**

The Company's functional and presentational currency is GBP and the financial statements are rounded to the nearest £.

**Transactions and balances**

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

2.4 Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Balance sheet date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021**

---

**2. Accounting policies (continued)**

**2.5 Valuation of investments**

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of comprehensive income for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each Balance Sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

**2.6 Debtors**

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

**2.7 Cash and cash equivalents**

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

**2.8 Creditors**

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

**2.9 Financial instruments**

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the case of a small company, or a public benefit entity concessionary loan.

Investments in non-derivative instruments that are equity to the issuer are measured:

- at fair value with changes recognised in the Statement of comprehensive income if the shares are publicly traded or their fair value can otherwise be measured reliably;

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021

---

2. Accounting policies (continued)

2.9 Financial instruments (continued)

- at cost less impairment for all other investments.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or income as appropriate. The company does not currently apply hedge accounting for interest rate and foreign exchange derivatives.

2.10 Dividends

Dividend income is recognised when the right to receive payment is established.

3. Employees

The average monthly number of employees, including directors, during the year was 3 (2020 - 3).

4. Income from investments

	2021 £	2020 £
Dividends received from unlisted investments	-	2,001,600
	<u>-</u>	<u>2,001,600</u>
	<u>-</u>	<u>2,001,600</u>

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021**

---

**5. Fixed asset investments**

	Investments in subsidiary companies £	Listed investments £	Total £
<b>Cost or valuation</b>			
At 1 April 2020	24,401,126	105,037	24,506,163
Additions	2,289,660	-	2,289,660
Revaluations	-	249,947	249,947
At 31 March 2021	<u>26,690,786</u>	<u>354,984</u>	<u>27,045,770</u>
<b>Impairment</b>			
At 1 April 2020	4,587,871	-	4,587,871
Charge for the period	2,262,981	-	2,262,981
At 31 March 2021	<u>6,850,852</u>	<u>-</u>	<u>6,850,852</u>
<b>Net book value</b>			
At 31 March 2021	<u>19,839,934</u>	<u>354,984</u>	<u>20,194,918</u>
At 31 March 2020	<u>19,813,255</u>	<u>105,037</u>	<u>19,918,292</u>

**Subsidiary undertakings**

The following were subsidiary undertakings of the Company:

<b>Name</b>	<b>Registered office</b>	<b>Class of shares</b>	<b>Holding</b>
Strides Pharma UK Ltd	Unit 4 The Metro Centre, Dwight Road, Watford, WD18 9SS	Ordinary	100%
Beltapharm S.p.A	Via Stelvio, 66, 20095, Cusano Milanino MI, Italy.	Ordinary	97.94%
Altima Innovations Inc	5th Floor Charles Hose, 108/110 Fubchley Road, London, United Kingdom, NW3 5JJ	Ordinary	100%

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021**

---

**5. Fixed asset investments (continued)****Subsidiary undertakings (continued)**

The aggregate of the share capital and reserves as at 31 March 2021 and the profit or loss for the year ended on that date for the subsidiary undertakings were as follows:

<b>Name</b>	<b>Aggregate of share capital and reserves £</b>	<b>Profit/(Loss) £</b>
Strides Pharma UK Ltd	9,689,006	2,048,483
Beltapharm S.p.A	2,208,733	279,413
Altima Innovations Inc	-	-

**6. Debtors**

	<b>2021 £</b>	<b>2020 £</b>
Amounts owed by group undertakings	87,925	496,378
	<b>87,925</b>	<b>496,378</b>

**7. Cash and cash equivalents**

	<b>2021 £</b>	<b>2020 £</b>
Cash at bank and in hand	170,288	16,232
	<b>170,288</b>	<b>16,232</b>

**8. Creditors: Amounts falling due within one year**

	<b>2021 £</b>	<b>2020 £</b>
Amounts owed to group undertakings	5,006,721	3,255,153
Accruals and deferred income	56,310	8,060
	<b>5,063,031</b>	<b>3,263,213</b>

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2021**

---

**9. Financial instruments**

	2021 £	2020 £
<b>Financial assets</b>		
Financial assets measured at fair value through profit or loss	<b>170,288</b>	105,037

Financial assets and liabilities measured at fair value through profit or loss comprise of listed investments.

**10. Share capital**

	2021 £	2020 £
<b>Allotted, called up and fully paid</b>		
22,086,538 (2020 - 22,086,538) Ordinary Shares shares of £1.00 each	<b>22,086,538</b>	22,086,538
212,709 (2020 - 212,709) Preference shares shares of £100.00 each	<b>21,270,900</b>	21,270,900
	<b>43,357,438</b>	43,357,438

**11. Related party transactions**

As the company is a wholly owned subsidiary of Strides Pharma Science Limited, the company has taken advantage of the exemption in FRS102 para 33.1A and has therefore not disclosed transactions or balances with other wholly-owned subsidiaries which form part of the group headed by Strides Pharma Science Limited.

At the year end the company was due £69,058 (2020: £72,411) from BeltaPharma S.p.A, a subsidiary company.

**12. Controlling party**

The company is owned by Strides Arcolab International Limited, a company registered in England and Wales. The ultimate parent company is Strides Pharma Science Ltd, an entity registered in India. The consolidated accounts are available at the registered address of the ultimate parent. The address is 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India. There is no ultimate controlling party.

The company is exempt from producing consolidated accounts as it is included in the consolidated accounts of the parent company.

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**DETAILED PROFIT AND LOSS ACCOUNT  
FOR THE YEAR ENDED 31 MARCH 2021**

---

	2021 £	2020 £
Administration expenses	<b>(1,980,066)</b>	(239,021)
Fair value movements	<b>249,947</b>	(1,129,482)
<b>Operating loss</b>	<b>(1,730,119)</b>	(1,368,503)
Investment income	-	2,001,600
<b>(Loss)/Profit for the year</b>	<b>(1,730,119)</b>	633,097

---

**STRIDES PHARMA GLOBAL (UK) LTD**

---

**SCHEDULE TO THE DETAILED ACCOUNTS  
FOR THE YEAR ENDED 31 MARCH 2021**

---

	2021	2020
	£	£
<b>Administration expenses</b>		
Legal and professional	980	240
Auditor's remuneration	6,040	2,702
Bank charges	267	83
Difference on foreign exchange	(290,202)	89,834
Impairment charge in subsidiaries	2,262,981	146,162
	<u>1,980,066</u>	<u>239,021</u>
	2021	2020
	£	£
<b>Investment income</b>		
Dividends received - unlisted investments	-	2,001,600
	<u>-</u>	<u>2,001,600</u>